Advanced Enzyme Technologies Ltd.
CIN: U24200MH1989PLC051018
Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India
Tel: +91-22-4170 3200, Fax: +91-22-2583 5159
Email: info@advancedenzymes.com, www.advancedenzymes.com

Date: October 28, 2016

To,
Listing Department
BSE Limited
25th Floor, Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

Listing Department
National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra-Kurla Complex, Bandra (E)
Mumbai- 400 051

Dear Sir/Madam,

Ref: ISIN: INE837H01012; Scrip ID-540025, Scrip Code-ADVENZYMES

Pursuant to Regulation 30(6) and other relevant clauses of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that an Analysts call on the acquisition of JC Biotech Pvt. Ltd. will be held at 4.30 P.M. on Friday, October 28, 2016.

Please find attached herewith the Conference Call Details.

Kindly take the same on your records.

Thanking you,

Yours Faithfully,
For **ADVANCED ENZYME TECHNOLOGIES LIMITED**

Prabal Bordiya
Company Secretary
Membership No. - A42028

Advanced Enzymes acquires 70% stake in API maker JC Biotech

Strengthens leadership in API Serratiopeptidase with 80%+ market share

Deal also enables Company's foray into Biopharma & Algal DHA

Projected to be EPS accretive in FY17

Mumbai, India: October 28, 2016 – Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES.NS; BSE:540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes, today announced that it has entered into definitive agreements with API maker JC Biotech to acquire a 70% stake for a consideration of Rs. 50 Crores. The proposed transaction was approved by the board of Advanced Enzymes today.

C L. Rathi, Managing Director, Advanced Enzymes, said, ***"We expect this deal to immediately strengthen our market leadership in API* Serratiopeptidase, *giving us significant competitive advantage as well as flexibility in production. JC Biotech has the ability to handle solvent based fermentation & recovery, which is highly complementary to our current production process."***

Headquartered in Hyderabad, JC Biotech is the manufacturer of API Serratiopeptidase, an anti-inflammatory enzyme, and has a R&D pipeline of biopharma molecules. It also has a fairly advanced technology for the manufacturing of algal DHA, an Omega 3 Fatty Acid which finds great application in Human Nutrition. JC Biotech has a production facility in Andhra Pradesh, and has the ability to expand its fermentation capacity of 60 m^3 further.

JC Biotech currently commands a 50%+ share in the Indian market, thereby taking Advanced Enzymes' combined market share to 80%+ post acquisition.

As of 31st March 2016, JC Biotech's revenues stood at Rs. 39 Crores, with a Profit After Tax (PAT) of Rs. 2.5 Crores.

The acquisition is expected to close latest by end of December 2016. Advanced Enzymes will finance the acquisition largely through internal accruals. Upon closing, the acquisition is expected to be accretive to Advanced Enzymes' EPS for FY17.

Copyright © 2016 Advanced Enzyme Technologies Ltd. All rights reserved.

About Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited is a research driven company with global leadership in the manufacturing of enzymes, incorporated in 1989. However, its journey began, when founder Late Shri L. C. Rathi set up India's first enzyme manufacturing plant in 1958. Since then, the company has continued to grow with that same entrepreneurial and innovative spirit and is today, the largest producer of enzymes in Central Asia. It is committed to serve the Human Nutrition, Animal Nutrition and Bio-Processing industries with its enzymatic solutions. The company aims to provide side-effect-free healthcare and eco-safe industrial solutions to its customers globally.

Equipped with state-of-the-art 6 manufacturing facilities and 4 research & development centres across India and US, Advanced Enzymes offers 400+ enzyme products. Advanced Enzymes exports to 45+ countries across 6 continents, and provides customized & effective enzyme solutions coupled with the best in technical advice & superior service.

Forward-looking statements

This press release may contain forward-looking statements with respect to Advanced Enzyme Technologies' future (financial) performance and position. Such statements are based on current expectations, estimates and information currently available to the company.
Advanced Enzyme Technologies Limited cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. The company has no obligation to update the statements contained in this press release, unless required by law.

For further details, contact:

Investor Relations
Piyush C. Rathi
Chief Business Officer
Tel: +91 22 4170 3200
Email: piyush@advancedenzymes.com

Advanced Enzyme Technologies Limited
Regd. Office: 5th Floor, 'A' Wing, Sun Magnetica, LIC Service Road, Louiswadi, Thane (W),
Mumbai -400 604
Tel: +91 22 4170 3200
www.advancedenzymes.com
CIN No: U24200MH1989PLC051018

Copyright © 2016 Advanced Enzyme Technologies Ltd. All rights reserved.